Conference Details - Agenda
View all Conferences
This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Continuing Education Information
Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Sixth Annual Symposium on the Future of Lung Cancer
Washington Marriott Hotel
Washington, DC
December 5, 2009
Saturday, Dec 5, 2009
| 7:30 am | Registration and Breakfast |
| 8:00 am | Welcome and Introductions Thomas Lynch |
| 8:05 am | Presession Survey |
| Hot Topics in Lung Cancer | |
| 8:10 am | Impact of Histology on Response and Patient Selection Nathan A. Pennell |
| 8:30 am | Question-and-Answer Session |
| 8:35 am | Debate: Early Second-line Therapy/Maintenance Therapy Is Standard of Care |
| Pro H. Jack West |
|
| Con Nasser H. Hanna |
|
| 9:05 am | Question-and-Answer Session |
| 9:10 am | Optimizing EGFR Inhibition in Lung Cancer Lecia V. Sequist |
| 9:30 am | Question-and-Answer Session |
| 9:35 am | New Indications for Antiangiogenic Agents David R. Spigel |
| 9:55 am | Question-and-Answer Session |
| 10:00 am | Roundtable Discussion |
| 10:20 am | Break |
| State-of-the-Art Approaches to the Treatment of NSCLC: Case-Based Discussions (NCCN Partnership Section) | |
| 10:35 am | Multidisciplinary Management of Locoregional NSCLC Todd Demmy, David S. Ettinger, Quynh-Thu Le |
| 11:35 am | Management of Metastatic NSCLC: Markers, Selection of Therapy, Maintenance Therapy, Supportive Care Todd Demmy, David S. Ettinger, Quynh-Thu Le |
| 12:35 pm | Postsession Survey |
| 12:45 pm | Break to Serve Lunch |
| 1:15 pm | Presession Survey |
| New Directions in Stage III NSCLC | |
| 1:25 pm | New Systemic Therapies in Locally Advanced NSCLC Ramaswamy Govindan |
| 1:45 pm | Question-and-Answer Session |
| 1:50 pm | Surgery in Locally Advanced NSCLC Frank C. Detterbeck |
| 2:10 pm | Question-and-Answer Session |
| Future Directions in Lung Cancer Therapy | |
| 2:15 pm | Inhibiting EML4-ALK in Lung Cancer Alice Tsang Shaw |
| 2:25 pm | Question-and-Answer Session |
| 2:30 pm | Novel Disruptors of Tumor Vasculature David R. Spigel |
| 2:40 pm | Question-and-Answer Session |
| 2:45 pm | Inhibiting Histone Deacetylases Suresh Ramalingam |
| 2:55 pm | Question-and-Answer Session |
| 3:00 pm | mTOR Inhibitors Bruce E. Johnson |
| 3:10 pm | Question-and-Answer Session |
| 3:15 pm | IGF-1R Inhibitors Corey Langer |
| 3:25 pm | Question-and-Answer Session |
| 3:30 pm | HSP90 Inhibitors Scott N. Gettinger |
| 3:40 pm | Question-and-Answer Session |
| 3:45 pm | Postsession Survey |
| 3:55 pm | Closing Remarks Thomas Lynch |
| 4:00 pm | Adjourn |
Educational Grants
An educational grant for this activity was provided by:
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Eli Lilly and Company
- Genentech BioOncology/
OSI Oncology - Merck Oncology
- Agennix, Inc.
- Novartis Oncology